^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CTL123
i
Other names: CTL123, CART123, CTL123 T cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
SignalRx
Drug class:
IL-3-targeted CAR-T immunotherapy
Related drugs:
over5years
[VIRTUAL] Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia (ASH 2020)
Also, the CAR is co-expressed with a suicide mechanism (RQR8), which can be activated by using rituximab...Pts receive a lymphodepletion (LD) regimen of either fludarabine and cyclophosphamide (FC) or fludarabine, cyclophosphamide plus alemtuzumab (FCA) starting on Day -5, followed by an infusion of UCART123 at one of 5 dose levels on Day 0...DL1 has cleared safety without DLT, and enrollment at the next dose levels are proceeding. ClinicalTrials.gov Identifier: NCT03190278
Clinical
|
CD123 (Interleukin 3 Receptor Subunit Alpha)
|
Rituxan (rituximab) • Campath (alemtuzumab) • fludarabine IV • UCART123 • CTL123 • cyclophosphamide intravenous
Share via
